These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 30217739)

  • 21. Construction and characterization of novel, recombinant immunotoxins targeting the Her2/neu oncogene product: in vitro and in vivo studies.
    Cao Y; Marks JD; Marks JW; Cheung LH; Kim S; Rosenblum MG
    Cancer Res; 2009 Dec; 69(23):8987-95. PubMed ID: 19934334
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Challenges associated with the targeted delivery of gelonin to claudin-expressing cancer cells with the use of activatable cell penetrating peptides to enhance potency.
    Yuan X; Lin X; Manorek G; Howell SB
    BMC Cancer; 2011 Feb; 11():61. PubMed ID: 21303546
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Assessing the therapeutic efficacy of VEGFR-1-targeted polymer drug conjugates in mouse tumor models.
    Shamay Y; Golan M; Tyomkin D; David A
    J Control Release; 2016 May; 229():192-199. PubMed ID: 27001892
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Light-controlled endosomal escape of the novel CD133-targeting immunotoxin AC133-saporin by photochemical internalization - A minimally invasive cancer stem cell-targeting strategy.
    Bostad M; Olsen CE; Peng Q; Berg K; Høgset A; Selbo PK
    J Control Release; 2015 May; 206():37-48. PubMed ID: 25758331
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Photochemical internalization (PCI) of immunotoxins targeting CD133 is specific and highly potent at femtomolar levels in cells with cancer stem cell properties.
    Bostad M; Berg K; Høgset A; Skarpen E; Stenmark H; Selbo PK
    J Control Release; 2013 Jun; 168(3):317-26. PubMed ID: 23567040
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Enhanced photodynamic destruction of a transplantable fibrosarcoma using photochemical internalisation of gelonin.
    Dietze A; Peng Q; Selbo PK; Kaalhus O; Müller C; Bown S; Berg K
    Br J Cancer; 2005 Jun; 92(11):2004-9. PubMed ID: 15886704
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Vascular targeting of ocular neovascularization with a vascular endothelial growth factor121/gelonin chimeric protein.
    Akiyama H; Mohamedali KA; E Silva RL; Kachi S; Shen J; Hatara C; Umeda N; Hackett SF; Aslam S; Krause M; Lai H; Rosenblum MG; Campochiaro PA
    Mol Pharmacol; 2005 Dec; 68(6):1543-50. PubMed ID: 16150930
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Chemically and biologically synthesized CPP-modified gelonin for enhanced anti-tumor activity.
    Shin MC; Zhang J; David AE; Trommer WE; Kwon YM; Min KA; Kim JH; Yang VC
    J Control Release; 2013 Nov; 172(1):169-178. PubMed ID: 23973813
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fusion of gelonin and anti-insulin-like growth factor-1 receptor (IGF-1R) affibody for enhanced brain cancer therapy.
    Ham S; Min KA; Yang JW; Shin MC
    Arch Pharm Res; 2017 Sep; 40(9):1094-1104. PubMed ID: 28900896
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Vascular endothelial cells as targets for photochemical internalization (PCI).
    Vikdal M; Weyergang A; Selbo PK; Berg K
    Photochem Photobiol; 2013; 89(5):1185-92. PubMed ID: 23819771
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Biodistribution, pharmacokinetics, and nuclear imaging studies of 111In-labeled rGel/BLyS fusion toxin in SCID mice bearing B cell lymphoma.
    Wen X; Lyu MA; Zhang R; Lu W; Huang Q; Liang D; Rosenblum MG; Li C
    Mol Imaging Biol; 2011 Aug; 13(4):721-9. PubMed ID: 20686856
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Quantitative Evaluation of Tumor Early Response to a Vascular-Disrupting Agent with Dynamic PET.
    Guo N; Zhang F; Zhang X; Guo J; Lang L; Kiesewetter DO; Niu G; Li Q; Chen X
    Mol Imaging Biol; 2015 Dec; 17(6):865-73. PubMed ID: 25896816
    [TBL] [Abstract][Full Text] [Related]  

  • 33. VEGFR2-Targeted Contrast-Enhanced Ultrasound to Distinguish between Two Anti-Angiogenic Treatments.
    Payen T; Dizeux A; Baldini C; Le Guillou-Buffello D; Lamuraglia M; Comperat E; Lucidarme O; Bridal SL
    Ultrasound Med Biol; 2015 Aug; 41(8):2202-11. PubMed ID: 25980323
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The vascular-ablative agent VEGF(121)/rGel inhibits pulmonary metastases of MDA-MB-231 breast tumors.
    Ran S; Mohamedali KA; Luster TA; Thorpe PE; Rosenblum MG
    Neoplasia; 2005 May; 7(5):486-96. PubMed ID: 15967101
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Enhancement of tumor growth and vascular density by transfection of vascular endothelial cell growth factor into MCF-7 human breast carcinoma cells.
    Zhang HT; Craft P; Scott PA; Ziche M; Weich HA; Harris AL; Bicknell R
    J Natl Cancer Inst; 1995 Feb; 87(3):213-9. PubMed ID: 7535859
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In vivo documentation of photochemical internalization, a novel approach to site specific cancer therapy.
    Selbo PK; Sivam G; Fodstad O; Sandvig K; Berg K
    Int J Cancer; 2001 Jun; 92(5):761-6. PubMed ID: 11340584
    [TBL] [Abstract][Full Text] [Related]  

  • 37. YM-359445, an orally bioavailable vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor, has highly potent antitumor activity against established tumors.
    Amino N; Ideyama Y; Yamano M; Kuromitsu S; Tajinda K; Samizu K; Hisamichi H; Matsuhisa A; Shirasuna K; Kudoh M; Shibasaki M
    Clin Cancer Res; 2006 Mar; 12(5):1630-8. PubMed ID: 16533791
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anti-flt1 peptide, a vascular endothelial growth factor receptor 1-specific hexapeptide, inhibits tumor growth and metastasis.
    Bae DG; Kim TD; Li G; Yoon WH; Chae CB
    Clin Cancer Res; 2005 Apr; 11(7):2651-61. PubMed ID: 15814646
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dual blockade of VEGFR1 and VEGFR2 by a novel peptide abrogates VEGF-driven angiogenesis, tumor growth, and metastasis through PI3K/AKT and MAPK/ERK1/2 pathway.
    Sadremomtaz A; Mansouri K; Alemzadeh G; Safa M; Rastaghi AE; Asghari SM
    Biochim Biophys Acta Gen Subj; 2018 Dec; 1862(12):2688-2700. PubMed ID: 30251659
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Novel drug delivery liposomes targeted with a fully human anti-VEGF165 monoclonal antibody show superior antitumor efficacy in vivo.
    Shi C; Cao H; He W; Gao F; Liu Y; Yin L
    Biomed Pharmacother; 2015 Jul; 73():48-57. PubMed ID: 26211582
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.